{
     "PMID": "27510168",
     "OWN": "NLM",
     "STAT": "In-Data-Review",
     "LR": "20170220",
     "IS": "2045-2322 (Electronic) 2045-2322 (Linking)",
     "VI": "6",
     "DP": "2016 Aug 11",
     "TI": "The caffeine-binding adenosine A2A receptor induces age-like HPA-axis dysfunction by targeting glucocorticoid receptor function.",
     "PG": "31493",
     "LID": "10.1038/srep31493 [doi]",
     "AB": "Caffeine is associated with procognitive effects in humans by counteracting overactivation of the adenosine A2A receptor (A2AR), which is upregulated in the human forebrain of aged and Alzheimer's disease (AD) patients. We have previously shown that an anti-A2AR therapy reverts age-like memory deficits, by reestablishment of the hypothalamic-pituitary-adrenal (HPA) axis feedback and corticosterone circadian levels. These observations suggest that A2AR over-activation and glucocorticoid dysfunction are key events in age-related hippocampal deficits; but their direct connection has never been explored. We now show that inducing A2AR overexpression in an aging-like profile is sufficient to trigger HPA-axis dysfunction, namely loss of plasmatic corticosterone circadian oscillation, and promotes reduction of GR hippocampal levels. The synaptic plasticity and memory deficits triggered by GR in the hippocampus are amplified by A2AR over-activation and were rescued by anti-A2AR therapy; finally, we demonstrate that A2AR act on GR nuclear translocation and GR-dependent transcriptional regulation. We provide the first demonstration that A2AR is a major regulator of GR function and that this functional interconnection may be a trigger to age-related memory deficits. This supports the idea that the procognitive effects of A2AR antagonists, namely caffeine, on Alzheimer's and age-related cognitive impairments may rely on its ability to modulate GR actions.",
     "FAU": [
          "Batalha, Vania L",
          "Ferreira, Diana G",
          "Coelho, Joana E",
          "Valadas, Jorge S",
          "Gomes, Rui",
          "Temido-Ferreira, Mariana",
          "Shmidt, Tatiana",
          "Baqi, Younis",
          "Buee, Luc",
          "Muller, Christa E",
          "Hamdane, Malika",
          "Outeiro, Tiago F",
          "Bader, Michael",
          "Meijsing, Sebastiaan H",
          "Sadri-Vakili, Ghazaleh",
          "Blum, David",
          "Lopes, Luisa V"
     ],
     "AU": [
          "Batalha VL",
          "Ferreira DG",
          "Coelho JE",
          "Valadas JS",
          "Gomes R",
          "Temido-Ferreira M",
          "Shmidt T",
          "Baqi Y",
          "Buee L",
          "Muller CE",
          "Hamdane M",
          "Outeiro TF",
          "Bader M",
          "Meijsing SH",
          "Sadri-Vakili G",
          "Blum D",
          "Lopes LV"
     ],
     "AD": "Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Universidade de Lisboa, Portugal. Max Planck Institute for Molecular Genetics, Berlin,Germany. Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Universidade de Lisboa, Portugal. Department of NeuroDegeneration and Restorative Research, University Medical Center Goettingen, Waldweg 33, 37073 Gottingen, Germany. Instituto de Farmacologia e Terapeutica, Faculdade de Medicina do Porto, Universidade do Porto, Portugal. Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Universidade de Lisboa, Portugal. Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Universidade de Lisboa, Portugal. Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Universidade de Lisboa, Portugal. Faculdade de Ciencias de Lisboa, Universidade de Lisboa, Portugal. Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Universidade de Lisboa, Portugal. Max-Delbruck-Center for Molecular Medicine (MDC), Berlin, Germany. PharmaCenter Bonn, Pharmazeutische Chemie I, Pharmazeutisches Institut, University of Bonn, Bonn, Germany. Department of Chemistry, Faculty of Science, Sultan Qaboos University, Muscat, Oman. Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Alzheimer &Tauopathies, Lille, France. PharmaCenter Bonn, Pharmazeutische Chemie I, Pharmazeutisches Institut, University of Bonn, Bonn, Germany. Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Alzheimer &Tauopathies, Lille, France. Department of NeuroDegeneration and Restorative Research, University Medical Center Goettingen, Waldweg 33, 37073 Gottingen, Germany. Max Planck Institute for Experimental Medicine, Goettingen, Germany. CEDOC, Centro de Estudos de Doencas Cronicas, Lisbon, Portugal. Max-Delbruck-Center for Molecular Medicine (MDC), Berlin, Germany. Charite-University Medicine Berlin, Germany. Institute of Biology, University of Lubeck, Germany. Max Planck Institute for Molecular Genetics, Berlin,Germany. MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, MA, United States of America. Univ. Lille, Inserm, CHU Lille, UMR-S 1172, Alzheimer &Tauopathies, Lille, France. Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Universidade de Lisboa, Portugal.",
     "LA": [
          "eng"
     ],
     "PT": [
          "Journal Article"
     ],
     "DEP": "20160811",
     "PL": "England",
     "TA": "Sci Rep",
     "JT": "Scientific reports",
     "JID": "101563288",
     "SB": "IM",
     "PMC": "PMC4980603",
     "EDAT": "2016/08/12 06:00",
     "MHDA": "2016/08/12 06:00",
     "CRDT": [
          "2016/08/12 06:00"
     ],
     "PHST": [
          "2016/04/07 00:00 [received]",
          "2016/07/01 00:00 [accepted]",
          "2016/08/12 06:00 [entrez]",
          "2016/08/12 06:00 [pubmed]",
          "2016/08/12 06:00 [medline]"
     ],
     "AID": [
          "srep31493 [pii]",
          "10.1038/srep31493 [doi]"
     ],
     "PST": "epublish",
     "SO": "Sci Rep. 2016 Aug 11;6:31493. doi: 10.1038/srep31493.",
     "term": "hippocampus"
}